GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that ...

Alliance News 5 March, 2024 | 11:03AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

ViiV Healthcare is a specialist HIV company majority owned by GSK, with Pfizer Inc and Shionogi & Co Ltd as shareholders. GSK is a Brentford, UK-based pharmaceutical maker.

Findings from a Phase One study, which were released by ViiV Healthcare at a conference on Tuesday, showed that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting, can be dosed at intervals of at least four months.

Data also showed that the intramuscular dosing of CAB-ULA has a safety and pharmacokinetic profile that supports a longer dose interval. According to GSK, these results are ViiV Healthcare's first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines.

ViiV Healthcare is currently conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.

GSK shares were trading 0.4% higher at 1,675.00 pence each in London on Tuesday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
GSK PLC 1,636.00 GBX -0.91
Pfizer Inc 26.27 USD -0.19

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures